PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24557496-7	2014	Moreover, ezetimibe suppressed the promoter activity of TNF-alpha but not TNF-alpha lacking the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) binding domain in THP-1 cells treated with phorbol myristate acetate and Chol:MbetaCD.	Ezetimibe	10-19	tumor necrosis factor	Homo sapiens	56-65	
22427252-8	2013	However, another inflammatory marker (tumor necrosis factor-alpha) was decreased significantly by ezetimibe (1.36 +- 1.06 in week 0 vs. 0.96 +- 0.24 in week 12, P = 0.042).	Ezetimibe	98-107	tumor necrosis factor	Homo sapiens	38-65	
28166606-7	2017	However, significantly greater reductions in plasma concentrations of tumour necrosis factor alpha (TNF-alpha) (SMD -0.48, 95% CI -0.87, -0.08; P = 0.018) were achieved with ezetimibe/statin combination therapy.	Ezetimibe	174-183	tumor necrosis factor	Homo sapiens	100-109	
28166606-8	2017	CONCLUSIONS: The results suggested that ezetimibe add-on to statin therapy is associated with an enhanced TNF-alpha-lowering effect compared with statin monotherapy.	Ezetimibe	40-49	tumor necrosis factor	Homo sapiens	106-115	
25931040-5	2015	Administration of simvastatin and statin/ezetimibe combination for 30 days reduced plasma levels of hsCRP, FFA, leptin, visfatin, and TNF-alpha but increased plasma levels of adiponectin, while the effect of ezetimibe was much more limited.	Ezetimibe	41-50	tumor necrosis factor	Homo sapiens	134-143	
25185849-6	2014	Administration of simvastatin and ezetimibe for 30 days reduced plasma levels of leptin, visfatin, TNF-alpha, as well as increased plasma levels of adiponectin.	Ezetimibe	34-43	tumor necrosis factor	Homo sapiens	99-108